SCHEMBL327765

SCHEMBL327765

Cc1ccc(N2CCCC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.64
MAPT P10636 8/20 0.58
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
KDM4E B2RXH2 5/20 0.58
L3MBTL1 Q9Y468 4/20 0.58
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
LMNA P02545 2/20 0.58
MCL1 Q07820 2/20 0.58
ALDH1A1 P00352 10/20 0.56
RECQL P46063 2/20 0.56
GAA P10253 3/20 0.54
ALOX15 P16050 2/20 0.54
HSD17B10 Q99714 2/20 0.54
USP2 O75604 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28567064 0.97 ADRB1 (0.61) ADRB1MAPTKMT2AMEN1KDM4E
SCHEMBL81881 0.97 ADRB1 (0.61) ADRB1MAPTKMT2AMEN1KDM4E
Hydrochloric Acid SCHEMBL16446845 0.97 ADRB1 (0.61) ADRB1MAPTKMT2AMEN1KDM4E
SCHEMBL82441 0.97 ADRB1 (0.61) ADRB1MAPTKMT2AMEN1KDM4E
Bromide SCHEMBL4039488 0.95 ADRB1 (0.59) ADRB1MAPTKMT2AMEN1KDM4E
SCHEMBL21065781 0.95 ADRB1 (0.59) ADRB1MAPTKMT2AMEN1KDM4E
Lithium SCHEMBL31448685 0.95 ADRB1 (0.59) ADRB1MAPTKMT2AMEN1KDM4E
SCHEMBL18118476 0.95 ADRB1 (0.64) ADRB1MAPTKMT2AMEN1KDM4E
SCHEMBL7105773 0.89 ADRB1 (0.70) ADRB1MAPTKMT2AMEN1KDM4E
SCHEMBL10063748 0.89 ADRB1 (0.70) ADRB1MAPTKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111712246-B Bis (hydroxymethyl) pyrrolopyrazine hybrid, preparation method and application thereof 周美吟 2025-05-06 CN disclosed
WO-2025028621-A1 MODIFIED CONJUGATED DIENE POLYMER, BALE, METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE POLYMER, RUBBER COMPOSITION, AND TIRE 旭化成株式会社 2025-02-06 WO disclosed
WO-2024137358-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2024-06-27 WO disclosed
US-20240167176-A1 STIRRING-FREE SCALABLE ELECTROSYNTHESIS ENABLED BY ALTERNATING CURRENT YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2024-05-23 US disclosed
WO-2024107393-A1 TRICYCLIC COMPOUNDS SCHRÖDINGER, INC. (US) 2024-05-23 WO disclosed
CN-114656389-B Synthesis method of 1-phenylpyrrolidine 河南大学 2023-12-15 CN disclosed
US-20230384496-A1 OPTICAL MEMBER FOR USE IN DISPLAY DEVICE AND DISPLAY DEVICE INCLUDING DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-11-30 US disclosed
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 US disclosed
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 US disclosed
WO-2000046214-A1 SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-08-10 WO disclosed
EP-0499266-B1 Endothelin antagonist TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1996-07-10 EP disclosed
EP-0626174-A2 Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-11-30 EP disclosed
US-5352659-A Polypeptide; hypotensive agents TAKEDA CHEMICAL INDUSTRIES (JP) 1994-10-04 US disclosed
US-5306808-A Endothelin derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-04-26 US disclosed
EP-0547317-A1 Endothelin antagonists TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-06-23 EP disclosed
EP-0499266-A1 Endothelin antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-08-19 EP disclosed
EP-0470256-A1 PEPTIDE DERIVATIVES AND PRODUCTION THEREOF Takeda Chemical Industries, Ltd. (JP) 1992-02-12 EP disclosed
WO-1991013089-A1 PEPTIDE DERIVATIVES AND PRODUCTION THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-09-05 WO disclosed
CN-86102906-A Preparation 1, the method for the two substituted imidazole  salt of 3- 1987-02-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators PDE4A, PDE4B, PDE5A ADRB1 687/4885MAPT 4661/4885KMT2A 4505/4885
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A ADRB1 4046/4885MAPT 3260/4885KMT2A 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.